London - Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru/Accrufer (ferric maltol), provides a business and unaudited trading update for the year ended 31 December 2020.

Operational highlights

Feraccru 2020 sales volumes in Europe increased by 70% year-on-year

China IND application submitted

First stage of paediatric study plan completed

Teva challenge to Shield's European patents withdrawn

Shield continues to evaluate options for launching Accrufer in the US

US partnering discussions remain ongoing with a number of parties

Financial highlights

Trading for the year was in line with market expectations

Revenues for 2020 expected to be GBP9.4 million (2019: GBP0.7 million)

Cash position as at 31 December 2020 was GBP2.9 million (2019: GBP4.1 million)

Shareholder loan facilities provide means to extend cash runway until late 2021

Contact:

Tim Watts

Tel: +44 (0)20 7186 8500

Web: www.shieldtherapeutics.com

About Shield Therapeutics plc

Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru/Accrufer, a novel, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru/Accrufer has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. Feraccru is commercialised in the UK and European Union by Norgine B.V. and the Company is currently in the process of evaluating commercialisation options for the US market, including the potential launch of Accrufer in the US by Shield. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru/Accrufer in China, Hong Kong, Macau and Taiwan.

(C) 2021 Electronic News Publishing, source ENP Newswire